STAT1 and neoplasm: Furthermore, tyrosine kinase inhibitors (TKIs), such as regorafenib, have been shown to enhance tumor antigen presentation and stimulate antitumor immunity through the activation and phosphorylation of STAT1 by IFN-γ, promoting HLA-I expression in liver cancer cells (169).